Arbutus Biopharma Corporation (ABUS) financial statements (2020 and earlier)

Company profile

Business Address 100-8900 GLENLYON PARKWAY
BURNABY, BC V5J 5J8
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:91125126131181069
Cash and cash equivalents323754231677269
Short-term investments5988721071540 
Other undisclosed cash, cash equivalents, and short-term investments     (112) 
Receivables1211130
Deferred costs      0
Income taxes receivable0
Other undisclosed current assets232111141
Total current assets:9412912913318411670
Noncurrent Assets
Property, plant and equipment910127321
Long-term investments and receivables 22  10  
Long-term investments 22  10  
Intangible assets, net (including goodwill) 6683124515 
Goodwill 222424163  
Intangible assets, net (excluding goodwill) 445999353  
Restricted cash and investments  1313   
Other noncurrent assets0      
Other undisclosed noncurrent assets3      
Total noncurrent assets:129910814352821
TOTAL ASSETS:10622823727671211872
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:791110994
Accounts payable23233  
Accrued liabilities11112  
Other undisclosed accounts payable and accrued liabilities4585594
Restructuring reserve01    
Deferred revenue and credits30163
Other undisclosed current liabilities1011155
Total current liabilities:8111511112013
Noncurrent Liabilities
Long-term debt and lease obligation  1212   
Long-term debt, excluding current maturities  1212   
Liabilities, other than long-term debt34285015410(0)
Deferred revenue and credits1 010(0)
Deferred rent credit 1
Deferred tax liabilities, net 1741146  
Business combination, contingent consideration, liability331097 
Other undisclosed noncurrent liabilities2213    0
Total noncurrent liabilities:2516406215410 
Total liabilities:332855731653013
Stockholders' equity
Stockholders' equity attributable to parent, including:732001822035488859
Preferred stock  49    
Common stock899879876867834290217
Additional paid in capital55484337302625
Accumulated other comprehensive loss(48)(48)(48)(50)(50)(22)(16)
Accumulated deficit(970)(805)(738)(651)(267)(206)(167)
Warrants and rights outstanding     55
Other undisclosed stockholders' equity attributable to parent1371261  (5)(5)
Total stockholders' equity:732001822035488859
TOTAL LIABILITIES AND EQUITY:10622823727671211872

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net111251516
Gross profit:66111251515
Operating expenses(150)(96)(122)(493)(127)(48)(28)
Operating loss:(144)(90)(111)(492)(102)(33)(12)
Nonoperating income (expense)(22)28222552
Investment income, nonoperating22821111
Foreign currency transaction gain (loss), before tax0(1)212241
Interest and debt expense(2)(0)(0)    
Other undisclosed income from continuing operations before equity method investments, income taxes 00    
Loss from continuing operations before equity method investments, income taxes:(168)(61)(109)(489)(77)(28)(11)
Other undisclosed income from continuing operations before income taxes2      
Loss from continuing operations before income taxes:(166)(61)(109)(489)(77)(28)(11)
Income tax benefit1342410516  
Net loss:(154)(57)(84)(384)(61)(28)(11)
Other undisclosed net loss attributable to parent     (11)(4)
Net loss attributable to parent:(154)(57)(84)(384)(61)(39)(14)
Preferred stock dividends and other adjustments(11)(10)(1)    
Net loss available to common stockholders, diluted:(165)(67)(85)(384)(61)(39)(14)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(154)(57)(84)(384)(61)(28)(11)
Other comprehensive income (loss)(0)0     
Comprehensive loss:(154)(57)(84)(384)(61)(28)(11)
Other undisclosed comprehensive loss, net of tax, attributable to parent    (27)(17)(7)
Comprehensive loss, net of tax, attributable to parent:(154)(57)(84)(384)(89)(45)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: